Private equity firm Advent to sell drugmaker Zentiva to GTCR

Zentiva as

11/09/2025 13:48

Sept 11 (Reuters) - Czech generic drugmaker Zentiva 1SKF401E.BV said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value.

The Financial Times had first reported the deal on Wednesday, saying it was worth 4.1 billion euros ($4.80 billion).

($1 = 0.8540 euros)

 (Reporting by Unnamalai L in Bengaluru; Editing by Maju Samuel)

 ((Unnamalai.L@thomsonreuters.com;))